Abstract Book

S902

ESTRO 37

Material and Methods The survey was conducted among patients presenting for radiotherapy (RT) of either breast or prostate cancer. 975 patients were screened and 200 of those were smartphone users, completed the survey before starting radiotherapy and were requested to complete it once more after completion of RT. Areas covered by the questionnaire were habits of smartphone usage, technical knowledge and abilities, readiness to use a mobile application (MA) within the context of RT, possible features of the MA, timeframe of reachability via smartphone notification and general attitude towards different aspects of RT. Results Median patient age was 51 years (range 35-75). 84,7% of the participants could use their smartphones with little to no help. 76,9% had not used their smartphones in a medical context before, however the majority showed high interest in using a MA for supportive care during RT (69,3%) or after its completion as part of follow-up (76,9%). Favored features of such a MA would include appointment-making (92,3%), collection of patient- reported outcome regarding their illness, therapy and general well-being (46,2%) and regular inquiries for the early detection of therapy-related toxicity (77,0%). The preferred usage frequency of support via MA was indicated as weekly (53,8%) or at the beginning of RT and its completion (23,1%) and was thus higher than the preferred frequency of consultations with a physician during RT (30,8% weekly, 46,2% beginning and completion of RT, 46,2% only as required). Conclusion Mobile applications for supportive care and follow-up of oncologic patients represent a promising field in the development of new patient-centered therapy concepts. The use of a MA in oncology is not quite widespread yet, however interest and acceptance among patients, especially in the field of radiation oncology is high. Compliance and consequently the success of this approach are highly dependent on the ease of use and safety of the respective application. The present survey serves as basis for further clinical trials in this field. EP-1680 Australian private practice rates of hypofractionated radiation therapy for early breast cancer P. O'Brien 1 , K. Neville 2 , M. Dreosti 3 , D. Blakey 4 , M. Latham 5 , S. Young 4 , M. McFadden 6 1 Genesis Cancer Care, Radiation Oncology, Gateshead, Australia 2 Genesis Cance Care, Radiation Oncology, Gateshead, Australia 3 Genesis Cancer Care, Radiation Oncology, Adelaide, Australia 4 Genesis Cancer Care, Radiation Oncology, Melbourne, Australia 5 Genesis Cancer Care, Radiation Oncology, Perth, Australia 6 Genesis Cancer Care, Radiation Oncology, Sydney, Australia Purpose or Objective Based on clinical trials involving more than 7,000 women, Cancer Australia guidelines recommend that hypofractionation should be considered for women over the age of 50 years with early stage breast cancer. Adoption of these recommendations has been variable. To date the only large scale analysis of fractionation practices from public hospitals in New South Wales (NSW)

demonstrated a hypofractionated schedule. Genesis Cancer Care is the largest private provider of radiation therapy services in Australia accounting for approximately 40% of all patients treated. This study aimed to investigate variation in hypofractionation across 4 states – Victoria, Western Australia, South Australia and NSW. Material and Methods The electronic medical record (MOSAIQ™) was interrogated to identify patients with T1 and T2, N0 breast cancer and receiving radiation therapy as adjuvant therapy between 2014 and 2016. The variables extracted included fractionation, laterality, patient age, treatment centre, radiation oncologist, distance from treatment centre, T stage, tumour grade, histopathological subtype (morphology) margin status, LVI, receptor status (ER, PR, Her2) and the use of chemotherapy. Summary statistics, univariate and multivariate modelling were then applied to the dataset. Results Of 3,473 patients treated 44% received a hypo- fractionated schedule. There was an increase in the use of hypofractionation in 2 states during this period. Uptake of hypofractionation varied by state (20--71%) and by radiation oncologist (3-100%). There was increasing use of hypofractionation with increasing age of the patient (61% for patients 70 years or older), lower tumour grade, ER positivity, but no difference by laterality or with increasing distance to treatment centre. Patients receiving chemotherapy were less likely to receive hypofractionation. On multivariate modelling increasing age, year of treatment, T stage, use of chemotherapy and Radiation Oncologist were all significant predictors of the use of hypofractionation (p<0.001). Conclusion Similar to other published experiences our data demonstrate variation in the uptake of hypofractionation for early stage breast cancer. Interestingly the overall rate of hypofractionation across this large private practice is very similar to the only other published Australian data. Radiation Oncologists(ROs) are more likely to use hypofractionation in older patients but there is variation between ROs and between states which is not explained by clinical factors. Our current plan is to explore whether rates of hypofractionation can be influenced by real time feedback to ROs using an in-house software development called RO Portal. This allows automatic download of structured data into Mosiaq and provision of patterns of practice dashboards to ROs. EP-1681 Loss of follow-up in cancer care for the management of cervix cancer patients J. Pandjatcharam 1 , P. Chinnakali 2 , V. Mohan 1 , N. Bharathnag 2 , K. Periasamy 1 , S.K. Soman 1 , K. Sri Harsha 1 1 JIPMER, Radiation Oncology, Puducherry, India 2 JIPMER, Preventive and Social Medicine, Puducherry, India 45% of patients received

Purpose or Objective 1.

To determine the proportion lost to follow up (LFU) among uterine cervix cancer patients at three stages of their disease managment namely before initiation of radiotherapy, between radiotherapy and evaluation for response and subsequent follow up till 4 months.